Kathryn Romano - Krystal Biotech Executive Officer
| KRYS Stock | USD 196.91 0.39 0.20% |
Executive
Kathryn Romano is Executive Officer of Krystal Biotech
| Age | 42 |
| Address | 2100 Wharton Street, Pittsburgh, PA, United States, 15203 |
| Phone | 412 586 5830 |
| Web | https://www.krystalbio.com |
Latest Insider Transactions
Kathryn Romano Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kathryn Romano against Krystal Biotech stock is an integral part of due diligence when investing in Krystal Biotech. Kathryn Romano insider activity provides valuable insight into whether Krystal Biotech is net buyers or sellers over its current business cycle. Note, Krystal Biotech insiders must abide by specific rules, including filing SEC forms every time they buy or sell Krystal Biotech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kathryn Romano over six months ago Exercise or conversion by Kathryn Romano of 2500 shares of Krystal Biotech subject to Rule 16b-3 |
Krystal Biotech Management Efficiency
The company has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0638 %, meaning that it created $0.0638 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Jim Flaherty | Rhythm Pharmaceuticals | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| Stephen MD | Regenxbio | 55 | |
| Jennifer Lee | Rhythm Pharmaceuticals | 48 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Alastair Garfield | Rhythm Pharmaceuticals | N/A | |
| Stuart Naylor | MeiraGTx Holdings PLC | 61 | |
| JD II | Regenxbio | 53 | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Sarah Ryan | Rhythm Pharmaceuticals | N/A | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| Olivier Danos | Regenxbio | 66 | |
| Ram PharmD | Regenxbio | 48 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Alastair Leighton | MeiraGTx Holdings PLC | N/A | |
| Christine Sheehy | MeiraGTx Holdings PLC | 56 | |
| Adam Townsend | Apellis Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0458 |
Krystal Biotech Leadership Team
Elected by the shareholders, the Krystal Biotech's board of directors comprises two types of representatives: Krystal Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Krystal. The board's role is to monitor Krystal Biotech's management team and ensure that shareholders' interests are well served. Krystal Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Krystal Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Wilson, Head Marketing | ||
| David Chien, Senior Development | ||
| Hubert MD, Senior Development | ||
| Gloria Lin, Accounting Mang | ||
| Kathryn Romano, Executive Officer | ||
| Katherine Tuminello, HR Mang | ||
| Suma Krishnan, President Founder | ||
| Stephane Paquette, Vice Development | ||
| Jennifer McDonough, Analytics Access | ||
| MS MBA, Chairman, Founder | ||
| John Karakkal, Vice Marketing | ||
| Ram Kamineni, Senior Operations | ||
| David Glynn, Commercial Counsel | ||
| John Thomas, General Secretary | ||
| Laurent Goux, Senior Europe | ||
| Andreas Orth, Ex Officer | ||
| Josh Suskin, Director Operations | ||
| Meg Dodge, Vice Communications | ||
| Kathryn CPA, Executive Officer |
Krystal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Krystal Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0458 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 5.08 B | ||||
| Shares Outstanding | 28.76 M | ||||
| Shares Owned By Insiders | 12.30 % | ||||
| Shares Owned By Institutions | 87.70 % | ||||
| Number Of Shares Shorted | 3.6 M | ||||
| Price To Earning | (6.36) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.